TheranosticTrials.org

Clinical Trial · NCT03873870

68Ga-DOTATATE PET for Management of Neuroendocrine Tumors

Overview

This is a research study to collect information regarding usefulness of positron emission tomography (PET) scans using a special dye called 68Ga-DOTATATE for patients with neuroendocrine tumours by determining the number of of patients whose clinical management was changed as a result of the scans.

Sponsor

University Health Network, Toronto

Phase

N/A

Contacts

Ur Metser, M.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03873870

Drug / Compound

DOTATATE

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • Any of the following indications:
  • Group D. As a problem-solving tool: As a problem-solving tool in patient with NET when confirmation of site of disease and/or disease extent may impact clinical management.
  • Approved by a review panel if Group D.
  • Group A. Identification of primary tumor: For the initial diagnosis of patients with clinical (e.g., signs, symptoms) and/or biochemical (e.g., tumor markers) suspicion of neuroendocrine tumours (NETs) but for whom conventional imaging is negative or equivocal or for whom biopsy is not easily obtained.
  • Group C. Restaging: Restaging of patients with NET where surgery or peptide-receptor radiotherapy (PRRT) is being considered; OR, where conventional imaging is negative or equivocal at time of clinical and/or biochemical progression.
  • Group B. Staging: For the staging of patients with localized primary NETs and/or limited metastasis where definitive surgery is planned.
  • Able to undergo PET/CT without sedation

Exclusion

  • Contraindication for PET examination as per institutional safety guidelines, including but not limited to pregnancy, or inability to lie still for PET examination.
  • Need for full sedation to undergo PET/CT scan.